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TheWnt pathway is abnormally activated in themajor-
ity of colorectal cancers, and significant knowledge
has been gained in understanding its role in tumor
initiation. However, the mechanisms of metastatic
outgrowth in colorectal cancer remain a major chal-
lenge. We report that autophagy-dependent meta-
bolic adaptation and survival of metastatic colorectal
cancer cells is regulated by the target of oncoge-
nic Wnt signaling, homeobox transcription factor
PROX1, expressed by a subpopulation of colon can-
cer progenitor/stem cells. We identify direct PROX1
target genes and show that repression of a pro-
apoptotic member of the BCL2 family, BCL2L15, is
important for survival of PROX1+ cells under meta-
bolic stress. PROX1 inactivation after the establish-
ment of metastases prevented further growth of
lesions. Furthermore, autophagy inhibition efficiently
targeted metastatic PROX1+ cells, suggesting a po-
tential therapeutic approach. These data identify
PROX1 as a key regulator of the transcriptional net-
work contributing to metastases outgrowth in colo-
rectal cancer.
INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of cancer-
related mortality. The prognosis is especially poor for metastatic
CRC, with overall 5-year survival rates of 5%–8% (CunninghamCell Reet al., 2010). Current treatment options include resection of sol-
itary metastases and combinations of anti-vascular endothelial
growth factor (VEGF) or epidermal growth factor receptor
(EGFR) inhibitors and cytotoxic therapy. However, these tar-
geted therapies are effective only in a small subset of patients
with metastatic disease and treatment benefits are short-lived,
further highlighting the need for a better understanding of meta-
static CRC (De Roock et al., 2011).
Wnt signaling is essential for the maintenance of normal
intestinal stem cells and is aberrantly activated in a significant
proportion of CRCs (Clevers, 2013). The evolutionary conserved
transcription factor PROX1 is a Wnt target gene in colon ade-
nomas, where it contributes to the transition from early to
dysplastic stage (Petrova et al., 2008). Prox1 is not expressed
in normal intestinal stem cells, demonstrating that only onco-
genic Wnt signaling triggers Prox1 expression (Petrova et al.,
2008). Increased epithelial-to-mesenchymal transition (EMT)
was recently reported in PROX1-expressing CRC cells in vitro
(Lu et al., 2012). However, the role of PROX1 in metastatic
CRC has not been investigated. Here, we report that PROX1 is
expressed in stem-like cells in a subset of Wnthigh colon car-
cinomas and metastases. PROX1 acts as a key regulator of
macrometastatic lesions outgrowth by promoting adaptation of
tumor cells to hypoxia and nutrient deprivation. Furthermore,
we show that targeting autophagy efficiently eliminates the
growth advantage of PROX1+ cells. We identify direct PROX1
target genes in CRC cells and show that a pro-apoptotic mem-
ber of BCL2 family, BCL2L15, is one of the downstream effectors
of PROX1. Our data thus identify a cancer-specific component of
the Wnt signaling required for outgrowth of metastases and sug-
gest that inhibition of PROX1, or PROX1-regulated pathways,
might constitute a new therapeutic approach.ports 8, 1957–1973, September 25, 2014 ª2014 The Authors 1957
(legend on next page)
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RESULTS
PROX1 Is Expressed in Progenitor/Stem Cells in Wnthigh
Colon Cancer Metastases
We examined whether PROX1 expression correlates with Wnt
signaling, stem-like/progenitor markers, cell differentiation, and
proliferation, using transcriptomes of 166 primary CRCs and
20 lung metastases (Sheffer et al., 2009). PROX1 expression
significantly correlated with stem/progenitor cell markers and
Wnt targets LGR5, ASCL2, RNF43, and EPHB2 (Clevers, 2013)
in primary tumors, and this correlation was further significantly
increased in lung metastases (Figure 1A; p < 0.05). In contrast,
PROX1 expression in metastases anticorrelated with the differ-
entiation marker KRT20 (Figure 1A). Analysis of the proliferation
signature MKI67, FOXM1, MYC, and AURKB (Jung et al., 2011)
revealed that PROX1 levels did not correlate with the signature
in primary tumors, whereas PROX1low metastases had a lower
proliferation index (Figure 1B).
We next asked how PROX1 expression correlates with mo-
lecular subtypes of CRC described by Budinska et al. (2013)
and Sadanandam et al. (2013). Highest PROX1 levels were
found in Wnthigh subtypes in both classification schemes (Fig-
ures S1A and S1B). In contrast, PROX1 was low in more-differ-
entiated subtypes, such as the subtype A with high expression
of differentiation markers and subtype C with high frequency of
cancer-specific DNA hypermethylation (CIMP-H) of the Budin-
ska et al. classification. Most of CIMP CRCs are also mismatch
repair (MMR) deficient due to hypermethylation of the MLH1
gene promoter (Truninger et al., 2005). In agreement with these
results, PROX1 was low in MMR-deficient CRCs (Figures S1C–
S1E). We further confirmed these data using the Pan-European
Trials in Alimentary Tract Cancers database, containing micro-
satellite instability status analysis for 688 CRC primary colon
carcinomas (Roth et al., 2010; Figure S1F).
The bioinformatics analysis predicted that PROX1 correlates
with stem/progenitor markers, high Wnt signaling, and prolifera-Figure 1. PROX1 Is Expressed in Stem-like Cells in Wnthigh CRC Metas
(A) PROX1 expression in CRC metastases correlates with activated Wnt pathwa
marker KRT20. Correlation analysis is based onGSE41258 (Sheffer et al., 2009). D
interquartile range (IQR).
(B) PROX1 expression in CRC metastases correlates with proliferation. Samples
three categories by PROX1-expression levels. The average expression of prolifer
area represents the average expression of all genes.
(C)WNThigh CRC stem cells produce higher levels of PROX1. Expression analysis i
and whiskers; Log expression values: 1.5 3 IQR.
(D) PROX1 protein is increased in CRC metastases. Samples were scored as sh
(E) Summary of PROX1 expression analyses in 33 primary tumors and metastas
(F) PROX1 protein levels correlate with proliferation in CRC metastases. Percen
corresponding lung (n = 10) and liver (n = 6) metastases. Data are presented as
(G) PROX1 is expressed in a subset of progenitor/stem cells in CRC metastases. S
amplesof cytoplasmicandmembranous localizationofb-catenin.Whitearrows: cell
(H and I) Quantification of PROX1 expression data shown in (G). PROX1 expressio
in PROX1+ tumor cells (I). Data are presented as mean ± SEM.
(J) Prox1 is expressed in a subset of mouse transformed intestinal stem/progen
EGFP-CreERT2 adenomas or normal intestine. Proliferating cells were identified
(K) Prox1 depletion decreases clonogenic growth of AKP organoids. AKP cells we
cells, and plated in Matrigel. Colony number /well was determined at day 15. Stu
(L) Prox1 mRNA levels in the control or shPROX1 transduced AKP organoids. St
(M and N) Stem/progenitor and Wnt target gene expression in AKP organoids fol
Cell Retion and anticorrelates with differentiation markers. Interrogation
of transcriptomes from human CRC stem cells, stratified by the
levels of Wnt signaling (de Sousa E Melo et al., 2011), demon-
strated that PROX1 was significantly higher in Wnthigh versus
Wntlow cancer stem cells (Figure 1C; p = 9.73 104). To evaluate
PROX1 protein levels in metastasis versus primary tumor, we
stained 33 matched primary CRCs and their metastases. Lung
and lymph node metastases had significantly higher levels of
PROX1 in comparison to the primary tumors, with a positive
trend for other metastatic sites (Figures 1D, 1E, and S1G). To
establish whether PROX1 is expressed in stem/progenitor cells,
we analyzed coexpression of PROX1 and EPHB2, CD44 and
BMI1, previously shown to encompass progenitor/stem cell
populations (Todaro et al., 2014; Martorell et al., 2014; Merlos-
Sua´rez et al., 2011; Kreso et al., 2014). We also analyzed b-cat-
enin nuclear/cytoplasmic localization as a marker of Wnt
pathway activation, proliferation, and differentiation. In agree-
ment with the bioinformatics analyses, differentiated KRT20+
cells did not express PROX1 and, in metastases, cell prolifera-
tion correlated with levels of PROX1 (Figures 1F and S1H–
S1J). The majority of PROX1+ cells also coexpressed EPHB2
and BMI1, 50% had nuclear/cytoplasmic b-catenin, and 17%
coexpressed CD44 or proliferation markers. A significant pro-
portion of EPHB2+, BMI1+, CD44+, and PH3+ cells did not ex-
press PROX1 (Figures 1G–1I). Thus, in human metastases,
PROX1 partially colocalizes with markers of stem/progenitor
cells, proliferation, and activated WNT signaling.
To extend our observations to a model with a well-character-
ized stem cell compartment, we analyzed adenomas from
Apcfl/fl;Lgr5-EGFP-Ires-CreERT2mice. GFP marks Lgr5+ normal
and transformed stem cells, which give rise to differentiated
progeny in both normal intestine and adenoma (Schepers
et al., 2012). Fifty to sixty percent of GFPhigh, GFPlow, EphB2+,
or proliferating 5-ethynyl-20-deoxyuridine (EdU)+ cells expressed
Prox1, whereas Prox1 was absent in differentiated lysozyme+
Paneth cells or Krt20+ enterocytes (Figures 1J and S1K). In linetases
y and stem-like/progenitor signature, and it anticorrelates with differentiation
ata are presented as box andwhiskers; Spearman correlation coefficient: 1.53
from primary tumors and lung metastases (Sheffer et al., 2009) were divided in
ation signature (black line) is plotted in log2 across the six categories. The gray
s based onGSE33112 (de Sousa EMelo et al., 2011). Data are presented as box
own in Figure S1C. Student’s t test with FDR correction; *p < 0.05.
es.
tages of PROX1+ and phosphohistone H3+ cells in primary tumors (n = 7) and
mean ± SEM.
taining for EPHB2, CD44, BMI1, b-catenin, and phosphohistone H3. Inserts: ex-
s coexpressingPROX1and the indicatedmarker. The scale bar represents50mm.
n in the indicated human tumor cell populations (H) or marker expression levels
itor cells. Staining for Prox1, GFP, EphB2, Krt20, or lysozyme in Apcfl/fl;Lgr5-
by EdU incorporation assay. The scale bar represents 20 mm.
re transduced with the control or PROX1 shRNAs, sorted to isolate single GFP+
dent’s t test; ***p < 0.001. Data are presented as mean ± SEM.
udent’s t test; **p < 0.01. Data are presented as mean ± SEM.
lowing Prox1 depletion at days 5 and 14. Data are presented as mean ± SEM.
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Figure 2. PROX1 Controls CRC Metastasis
(A) PROX1 levels in DLD1-PROX1, DLD1-PROX1mut, or control cells and tumor lysates. Western blotting for the indicated proteins.
(B) PROX1 promotes growth of metastases. Luciferase-tagged DLD1 cells overexpressing wild-type PROX1 (PROX1), mutated PROX1 (PROX1Mut), or trans-
fected with control vector (control) were implanted intracecally in nonobese diabetic (NOD)-severe combined immunodeficiency (SCID); IL-2Rg/ mice and
detected by bioluminescent imaging. The scale bar represents 8 mm.
(C) Comparable size of primary tumors. n = 9/group. Data are presented as box and whiskers; Tukey appearance.
(D) PROX1 overexpression does not affect metastasis incidence. Tumor cells were identified by staining for KRT20. Data are presented as box and whiskers;
Tukey appearance.
(E–G) PROX1 promotes growth of individual metastases. One-way ANOVA; *p < 0.05; ***p < 0.001. Data are presented as box and whiskers; Tukey appearance.
(legend continued on next page)
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with previous results, normal intestinal stem cells were Prox1
(Petrova et al., 2008; Figures 1J and S1L). These data show
that, as in human tissues, a subset of transformed intestinal
stem cells produces high levels of Prox1. Furthermore, a propor-
tion of GFPlow/EphB2+/EdU+ adenoma progenitor cell popula-
tion, but not more-differentiated cells, maintain Prox1 expres-
sion. We conclude that (1) PROX1 expression partially overlaps
with other cancer stem cell (CSC)/progenitor markers, (2) many
proliferating cells in the tumors are PROX1-negative, (3) PROX1
is not expressed in differentiated cells, and (4) PROX1 expression
is increased in metastases in comparison to the primary tumors.
Thus, PROX1 is induced only upon transformation and it defines
a subset of cancer stem/progenitor cells, which themselves are
moderately proliferative but, when present in metastases, signify
high proliferative activity.
PROX1 Controls CSC Colony-Forming Ability
To study whether PROX1 contributes to the clonogenic
growth of CRC cells, we used intestinal organoids from Apcfl/fl;
KrasLsl-G12D; Tp53fl/fl;villin-CreERT2 (AKP) mice. In addition to
high Wnt signaling, such intestinal epithelial cells carry an onco-
genic mutation in Kras and loss of the tumor suppressor p53,
thus recapitulating major pathways important for development
of CRC (Fearon, 2011). Similar to human CRCs and Apcfl/fl;
Lgr5-EGFP-Ires-CreERT2 adenomas, we observed partially
overlapping localization of Prox1 and intestinal stem cell/pro-
genitor markers Lgr5, nuclear b-catenin, EphB2, and Cd44; pro-
liferation markers phosphohistone H3 and Ki67; and absence of
Prox1 expression in differentiated Krt20+ and Krt6+ cells (Figures
S1M and S1N). We next tested whether Prox1 is necessary to
sustain growth of AKP organoids in a colony-forming assay,
where a single stem cell gives rise to a 3D ‘‘organoid’’ structure
(Sato et al., 2011). Downregulation of Prox1 significantly
decreased the number of colonies formed by single AKP cells,
thus demonstrating that Prox1 maintains clonogenic growth
(Figures 1K and 1L). Expression of progenitor/stem cell markers
and Wnt target genes Lgr5, Ascl2, Rnf43, and EphB2 was not
modified in early organoids at day 5, despite downregulation of
Prox1 (Figure 1M). However, their expression was lower in orga-
noids by day 15 (Figure 1N). Taken together with our previous
data showing that Prox1 does not affect general Wnt reporter ac-
tivity (Petrova et al., 2008), these results indicate that Prox1 does
not directly regulate stem/progenitor gene expression or general
Wnt signaling, but it rather maintains the clonogenic capacity of
CSCs.
PROX1 Controls CRC Metastasis
Analyses of human tumor samples indicated that PROX1
expression is elevated in a subset of metastases (Figure 1E),
consistent with potential involvement of PROX1 in metastatic
CRC. To clarify this, we used an orthotopic model, in which
CRC cells formmetastases in lymph nodes, liver, and lungs after
intracecal injection (Ce´spedes et al., 2007). To study if PROX1 is(H) Only wild-type PROX1 promotes growth of metastases. Upper row: increase
DLD1-PROX1 metastases. Arrows, necrotic areas. Lower row: increased prolifera
fluorescent staining for phosphohistone H3 (red), KRT20 (green), and DNA (blue).
panel).
Cell Resufficient to promote metastasis, we overexpressed PROX1 and
its inactive form PROX1mut, bearing mutations in the DNA-bind-
ing domain, in PROX1-negative DLD1 CRC cells. As another
control, we used cells transfected with an empty vector (Fig-
ure 2A). The primary tumor size was similar between the groups,
and there was no difference in primary tumor weights (Figures 2B
and 2C). However, significantly more DLD1-PROX1 cells were
present in lungs, liver, and lymph nodes (Figure 2B). Metastatic
incidence was increased only in lymph nodes of PROX1 group
(Figure 2D). In all tissues, PROX1+ metastases were 2- to
5-fold larger than the control lesions (Figures 2E–2G). PROX1+
metastases displayed higher levels of proliferation marker phos-
phohistone H3. Strikingly, proliferating cells were observed
throughout the lesion in DLD1-PROX1 metastases, whereas in
the control, metastases proliferation was restricted to the outer
rim as a result of massive central necrosis (Figure 2H).
We next asked whether PROX1 depletion in PROX1+ SW620
cells affects development of metastases (Figures S2A–S2C).
Depletion of PROX1 did not affect growth of primary tumors;
however, we observed marked differences in the development
of metastases (Figures S2D–S2F). In this case, there were
more PROX1+ metastases, which were also bigger in compari-
son to the controls (Figures S2E and S2F). Depletion of PROX1
reduced metastases proliferation and induced extensive necro-
sis and apoptosis, whereas little cell death was observed in pri-
mary tumors (Figures S2G and S2H).
To confirm that these phenotypes were not the result of long-
term cell selection, we studied SW480R/PROX1si cells, in which
PROX1 is suppressed upon administration of doxycycline (Pet-
rova et al., 2008; Figure S2I). Depletion of PROX1 reduced me-
tastases size and incidence without affecting the primary tumor
(Figures S2J and S2K). Doxycycline treatment had no effect on
SW480R/GFPsi metastases, in which a control small hairpin
RNA (shRNA) was induced (Figures S2J and S2L). Similar to
other models, suppression of PROX1 resulted in formation of
large central necrotic areas (Figure S2M). In summary, loss-
and gain-of-function experiments show that PROX1 is necessary
and sufficient to promote CRC metastases.
PROX1 Fuels Metastases Outgrowth
Metastasis requires several steps: invasion, extravasation, sur-
vival in the circulation, colonization of distal organs, and
outgrowth of macrometastases (Chaffer and Weinberg, 2011).
PROX1 promoted EMT in vitro by suppressing E-cadherin (Lu
et al., 2012). However, in our hands, PROX1 and PROX1+ cells
expressed comparable levels of E-cadherin and EMT marker vi-
mentin (Figures 3A and S3A). PROX1 did not increase invasion in
in vitro assays or local invasion in primary tumors, and vascular
density was comparable in PROX1+ versus PROX1 tumors (Fig-
ures S3B–S3E). Thus, enhanced local invasion and angiogenesis
are not major contributing factors in our models.
To test the role of PROX1 during the subsequent steps of
metastasis, we injected enhanced GFP (EGFP)-tagged SW620d size of DLD1-PROX1 lung metastases. Middle row: decreased cell death in
tion in DLD1-PROX1 metastases. Chromogenic staining for KRT20 (brown) or
The scale bars represent 200 mm (upper and middle panels) and 100 mm (lower
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Figure 3. PROX1 Promotes Metastatic Outgrowth
(A) Lungmicrometastases 3 days after the tail vein injection of SW620-shCtr or SW620-shPROX1 cells. Staining for PROX1 (red), vimentin (green), and DNA (blue).
The scale bar represents 20 mm.
(B) PROX1 is dispensable for tumor cell extravasation. Number of lung metastatic foci after injection of SW620-shCtr or SW620-shPROX1cells into the tail vein of
NOD-SCID; IL-2Rg/ mice. Tumor cells were stained for human vimentin. Data are presented as mean ± SEM.
(C) PROX1 promotes growth of metastases. Average size was calculated by dividing total metastases area by number of metastases and normalized to tissue
area analyzed. Two-way ANOVA; *p < 0.05; ***p < 0.001. Data are presented as mean ± SEM.
(D) PROX1 depletion prolongs survival. Kaplan-Meyer survival curve of mice injected with SW620-shCtr or SW620-shPROX1 cells. Log rank (Mantel-Cox) test;
***p < 0.001.
(E) PROX1 depletion prevents growth of macrometastases. Ex vivo analysis of SW620-shCtr and SW620shPROX1 EGFP+ cells 7 weeks after tail vein injection
into NOD-SCID; IL-2Rg/ mice. The scale bars represent 750 mm (lung), 1 mm (liver), and 2.5 mm (lymph node and dorsal muscle).
(legend continued on next page)
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PROX1+ and PROX1 cells into the tail vein. PROX1+ or PROX1
CRC cells formed similar number of lung colonies at days 2, 5,
and 7 post-injection (Figures 3A and 3B). Thus, PROX1 is
dispensable for tumor cell survival in the blood stream or in early
metastases. However, PROX1 depletion prevented further met-
astatic outgrowth and increased animal survival (Figures 3C and
3D). PROX1 cells were unable to establish colonies in most or-
gans, with a notable exception of skeletal muscle (Figures 3E
and 3F). Similar to orthotopic models, proliferation and apo-
ptosis were increased and decreased, respectively, in PROX1+
metastases compared to PROX1 lesions, as determined by
phosphohistone H3 staining and TUNEL assay (Figures 3G and
3H). Overall, these results indicate that PROX1 mainly promotes
outgrowth of tumor cells in target organs.
PROX1 Promotes Resistance to Hypoxia and
Nutrient Deprivation
To investigate the underlying mechanism of PROX1-mediated
metastatic outgrowth, we analyzed cell growth under standard
cell culture conditions. Modulation of PROX1 levels in three hu-
man CRC lines did not affect cell growth in 2D (Figures 4A and
S4A). We next studied the ability of these cells to form tumor
spheroids. In agreement with AKP organoid results, in all three
lines, PROX1+ spheroid size and number were increased in
comparison to PROX1-negative spheroids (Figures 4B–4E and
S4B–S4D). Consistent with in vivo models, PROX1+ spheroids
proliferated more and underwent apoptosis less than PROX1
spheroids (Figures 4F–4I and S4D).
In tumor spheroids, diffusion of nutrients and oxygen is
decreased in the center, resulting in a hypoxic/low-nutrient envi-
ronment and cell death (Hirschhaeuser et al., 2010). Whereas the
central part of PROX1 spheroids was filled with dead cells,
PROX1+ spheroids cores contained live cells and more cells
proliferated at a distance from the surface (Figure 4J), suggest-
ing that PROX1 promotes cell survival and proliferation in hypox-
ia and nutrient-poor environments. To directly test this, we
cultured DLD1-PROX1 and DLD1 control cells in 0.1% O2 and/
or under reduced glucose or glutamine conditions. Hypoxia
induced stabilization of HIF1a in both PROX1 and PROX1+
DLD1 cells (Figures 5A and 5B). However, by 72 hr, DLD1 control
cells became growth arrested and apoptotic, as determined by
staining for activated caspase-3 (Figures 5C–5F). In contrast,
hypoxic DLD1-PROX1 cells had somewhat enhanced prolifera-
tion and low cell death (Figures 5D, 5F, and 5G). PROX1+ cells
were also more resistant to cell growth arrest and cell death eli-
cited by the low glucose or glutamine, but not by etoposide,
which induces apoptosis through DNA damage (Figures 5D,
5F, 5G, and S5A). Similar results were observed in another cell
line SW620 (Figures S5A–S5D). These data indicate that
PROX1 sustains cell survival and proliferation under metabolic
stress.(F) Quantification of macrometastases size. Student’s t test; *p < 0.05; ***p < 0.0
(G) Increased proliferation (upper row) and decreased necrosis (lower row) in SW6
(green), and DNA (blue) or chromogenic TUNEL assay (brown). The scale bars re
(H) Quantification of cell proliferation or apoptosis in metastases. Proliferating cell
assay. Two-way ANOVA; **p < 0.01; ***p < 0.001. Data are presented as mean ±
Cell RePROX1 Promotes Metabolic Adaptation
Increased glycolysis is one of the key characteristics of cancer
cells. However, cancer cells can also use oxidative phosphoryla-
tion rather than glycolysis to sustain growth (e.g., Haq et al.,
2013; Janiszewska et al., 2012). To better understand the mech-
anisms of increased fitness of PROX1+ CRC cells, we studied
their metabolic responses upon nutrients or oxygen deprivation.
Extracellular acidification rate (ECAR), a measure of glycolysis,
and cellular oxygen consumption rate (OCR), a measure of
oxidative phosphorylation, were comparable between DLD1-
PROX1+ and PROX1 cells under basal cell culture conditions
(Figures 5H and 5I). As expected, glucose deprivation decreased
glycolysis in both cells types (Figure 5H). PROX1 cells dis-
played little compensatory increase in OCR, indicative of their
inability to switch to an alternative fuel source. In contrast,
OCR was high in PROX1+ cells upon glucose deprivation, which
also paralleled increased survival of PROX1+ cells (Figures 5I
and 5G). In the absence of glutamine, PROX1+ cells, unlike the
control cells, sustained both OCR and ECAR and increased
glycolysis after treatment with the mitochondrial oxidative phos-
phorylation inhibitor trifluorocarbonylcyanide phenylhydrazone
(Figures S5E and S5F). Better adaptation to glucose or glutamine
starvation and oxidative phosphorylation inhibition was also
observed in PROX1+ SW620 cells (data not shown).
In order to evaluate cell metabolism in hypoxia, we measured
ECAR and OCR in cells cultured for 24 hr in 0.1% O2. SW620
PROX1+ cells had higher basal level of oxidative phosphorylation
in normoxia and also displayed a higher glycolysis rate in
response to hypoxia (Figures S5G and S5H). Similarly, DLD1-
PROX1 cells cultured in hypoxia and low glutamine displayed
higher levels of glycolysis in comparison to the control cells
(data not shown). Taken together, these data indicate that,
whereas not favoring either oxidative phosphorylation or glycol-
ysis, PROX1 promotes cell adaption to changes in fuel source.
Such metabolic fitness of PROX1+ cells would confer growth
advantages under unfavorable conditions that tumor cells en-
counter during metastasis outgrowth.
Continuous PROX1 Expression Is Necessary for
Growth CRC Metastases
To evaluate the therapeutic potential of targeting PROX1, we
studied whether ablation of PROX1 affects established metasta-
ses. SW480R/PROX1si cells, expressing a PROX1-targeting
shRNA under the control of doxycycline, were injected intra-
cecally. Doxycycline treatment was initiated 30 days later,
when both primary and metastatic lesions already developed.
PROX1 depletion did not affect primary tumors, despite downre-
gulation of PROX1 protein (Figures 6A, 6B, and S6A). However,
further growth of metastases was arrested in the absence of
PROX1, whereas they continued to grow in the control mice (Fig-
ures 6A, 6C, S6B, and S6C). Thus, PROX1 inhibition may be a01. Data are presented as box and whiskers; Tukey appearance.
20shCtr liver metastasis. Staining for human vimentin (red), phosphohistone H3
present 50 mm (upper) and 100 mm (lower).
s were determined by staining for phosphohistone H3 and apoptosis by TUNEL
SEM.
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Figure 4. PROX1 Promotes Cell Growth and Survival in 3D
(A) PROX1 does not affect cell growth in 2D conditions. Growth curves of DLD1 PROX1 control or PROX1Mut and SW620 shCtr or shPROX1 cells. Two-way
ANOVA; not significant (ns). Data are presented as mean ± SEM.
(B) PROX1 promotes growth of tumor spheroids. Cells seeded in qGel were cultured in complete culturemedium and spheroid size determined by phase-contrast
microscopy. Threshold >500 mm2 was used. Two-way ANOVA; ***p < 0.001. Data are presented as mean ± SEM.
(C) Macroscopic view of tumor spheroids. Cells were stained for F-actin (green) 21 days after seeding. The scale bar represents 2.5 mm.
(D) Microscopic appearance of PROX1, control, or PROX1Mut spheroids at day 15. The scale bar represents 200 mm.
(E) Quantification of spheroids number at day 21. Data are presented as mean ± SEM.
(F) PROX1 promotes proliferation of spheroids. Whole-mount staining for phosphohistone H3 (red), F-actin (green), PROX1 (light blue), and DNA (dark blue). The
scale bar represents 100 mm.
(legend continued on next page)
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useful therapeutic option for treatment of PROX1+ CRC
metastases.
Pharmacological Inhibition of Autophagy Targets
Metastatic PROX1+ Cells
With few exceptions, therapeutic targeting of transcription fac-
tors is difficult (Koehler, 2010). Therefore, we sought to identify
pharmacological approaches for targeting PROX1+ CRC cells.
One of the pathways that mediate stress-induced metabolic
adaptation is autophagy, a process of recycling cell components
to maintain nutrient flux and energy homeostasis (White, 2012).
To test whether autophagy underlies PROX1-induced survival
under metabolic stress, we treated cells with chloroquine (CQ),
which inhibits autophagy by preventing endosomal acidification.
CQ-treated PROX1+ and PROX1 cells accumulated enlarged
LC3B+ autophagosomes in hypoxia, demonstrating efficient
autophagy inhibition (Figure S6D). CQ prevented proliferation
of hypoxic PROX1+ cells, whereas it had little effect on
PROX1+ or PROX1 cells under normoxic conditions (Figures
6D, 6E, and S5E). We also treated cells with another autophagy
inhibitor, 3-methyl adenine (3-MA) (White, 2012). Similar to the
CQ, 3-MA induced cell death of PROX1+ cells under hypoxic
conditions (Figure S6F). Thus, autophagy inhibition and meta-
bolic stress induce a synthetically lethal phenotype in PROX1+
cells. It also suggests that autophagy inhibition, which is now un-
der clinical trials in metastatic CRC (http://clinicaltrials.gov/
show/NCT01006369), may preferentially target PROX1+ tumor
cells.
To evaluate this hypothesis, we injected mice intravenously
with PROX1+ or PROX1 SW620 cells and monitored the effects
of CQ on liver metastases. CQ was administered either at high
(40 mg/kg; Sasaki et al., 2012) or at low (10 mg/kg) dosage,
which better mimics the situation in patients (Kimura et al.,
2013). The high-CQ regimen significantly reduced the size, but
not the number, of liver metastases (Figures S6G and S6H).
Strikingly, these macrometastases had increased necrosis,
with frequently only a rim of live cells (Figures S6I and S6J).
PROX1 cells did not form liver macrometastases at this time
point, and CQ had no further effect on cell death (Figures S6G–
S6I). Importantly, although low-CQ regimen did not reduce liver
macrometastasis incidence or size (Figures 6F and S6K), it still
strongly induced tumor necrosis and decreased cell proliferation
(Figures 6G, 6H, S6L, and S6M).
Decreased angiogenesis can also lead to tumor necrosis.
Therefore, we quantified tumor vessel density. Vascular density
was comparable in treated versus control metastases (Figures
6H and S6N), arguing that CQ acts directly on tumor cells. Prolif-
erating cells in CQ-treated tumors were found only at the tumor-
stroma interface, characterized by abundant vasculature,
showing that treated cells need oxygen- and nutrient-replete
conditions to proliferate (Figures 6H, S6L, and S6N).(G) Quantification of proliferation in tumor spheroids. Data are presented as box
(H) Decreased apoptosis in PROX1-expressing spheroids. Staining for TUNEL a
(I) Quantification of apoptosis, shown as percentage TUNEL+ cells in sections. DL
0.05; **p < 0.01. Data are presented as box and whiskers; Tukey appearance.
(J) Necrotic core is present in control but PROX1-expressing spheroids. Staining
represents 50 mm.
Cell ReIntriguingly, PROX1 had little effect on orthotopically im-
planted primary tumors, whereas it promoted growth of metas-
tases (Figures 2, 6A–6C, and S2). To explain this differential
response, we analyzed proliferation and apoptosis in metasta-
ses versus primary tumors. In two different models, PROX1+
and PROX1 primary tumors proliferated at low and comparable
rates and had low levels apoptosis (Figures 6I, 6J, and S6O; data
not shown). In contrast, proliferation was high in PROX1+ metas-
tases, whereas apoptosis was induced in PROX1 metastases
(Figures 6J and S6O). Because only PROX1+ cells can produc-
tively use autophagy (Figure 6D), we compared responses to
autophagy inhibition of primary tumors and metastases. Treat-
ment with CQ did not affect primary tumor proliferation (Figures
6K, 6L, and S6P) or metastasis incidence (Figure S6Q). However,
CQ significantly suppressed proliferation of PROX1+metastases
(Figures 6K and 6L). Furthermore, although CQ treatment did
induce some necrosis in primary tumors, necrosis levels were
significantly higher in PROX1+ metastases (Figure 6M). Im-
portantly, the treatment had no effect on vascular density
(Figure S6R).
To better understand why PROX1+metastases respond better
than primary tumors to autophagy inhibition, we next compared
autophagy in primary versus metastatic lesions by quantifying
differences in LC3B levels between the control and CQ-treated
lesions. Such autophagic flux is a more accurate measure of
autophagy than the steady-state level of processed LC3B (Miz-
ushima et al., 2010). Autophagic flux was higher in metastases,
regardless of the levels of PROX1 (Figures 6N–6Q). Our data
thus show that CQ efficiently targets PROX1+ cells in macrome-
tastases. They also indicate that the metastatic CRC cells have
higher levels of autophagy, which points to increased metabolic
stress in the sites of metastases. Although the mechanisms
remain to be elucidated, these results show that PROX1+ metas-
tases may respond to autophagy inhibition in patients.
BCL2L15 Is aDirect Target of PROX1,which Suppresses
Tumor Growth
To study the transcriptional network regulated by PROX1, we
carried out chromatin immunoprecipitation sequencing (ChIP-
seq) and transcriptome analysis after small interfering RNA
(siRNA)-mediated knockdown of PROX1 in SW480R cells (Fig-
ure S7A). The analyses identified 23,450 PROX1-binding sites
(false discovery rate [FDR] < 0.001) and 444 PROX1-dependent
genes (FDR < 0.05 and fold change [FC] > 1.5). To find how
PROX1 DNA binding correlates with changes in gene expres-
sion, we mapped these genes to nearby ChIP-seq-binding re-
gions. Unaffected genes (mean expression value >8 and FC <
1.5) were used as reference. We observed that PROX1 preferen-
tially binds in the vicinity of genes induced by PROX1 depletion
(Figure S7B). Thus, as found in other cell types (e.g., Steffensen
et al., 2004), PROX1 acts as a transcriptional repressor.and whiskers; Tukey appearance.
ssay (brown) and DNA (light blue). The scale bar represents 100 mm.
D1, one-way ANOVA; ***p < 0.001. SW620, Student’s t test; ***p < 0.001. *p <
for PH3 (red) and DNA (blue). White arrowheads, necrotic areas. The scale bar
ports 8, 1957–1973, September 25, 2014 ª2014 The Authors 1965
Figure 5. PROX1 Promotes Metabolic Adaptation In Vitro
(A) HIF1a is stabilized by hypoxia both in DLD1-PROX1 or control cells. Staining for HIF1a (green) and DNA (blue). The scale bar represents 50 mm.
(B) HIF1a levels in PROX1+ or PROX1 cells after 12 hr in hypoxia. Western blotting for the indicated proteins.
(C) PROX1+ cells proliferate in hypoxia. Cells were cultured in normoxia or 0.1% O2 for 72 hr. Staining for PH3 (red) and DNA (blue). The scale bar represents
50 mm.
(D) PROX1+ cells proliferate under metabolic stress. Cells were cultured in the indicated conditions for 72 hr and stained for phosphohistone H3 and DNA. Data
are presented as mean ± SEM.
(E) PROX1 reduces cell apoptosis under metabolic stress conditions. Staining for cleaved caspase-3 (green) and DNA (blue) after 72 hr. The scale bar represents
200 mm.
(F) Quantification of apoptosis for data shown in (E). One-way ANOVA; **p < 0.01; ***p < 0.001. Black *, PROX1 versus control. Two-way ANOVA; *p < 0.05; ***p <
0.001. Red *, treatment versus complete medium in normoxia. Data are presented as mean ± SEM.
(G) Quantification of DLD1 cell number after 3 days incubation in the indicated conditions. *p < 0.05; ***p < 0.001. Cell number was determined by CyQuant assay.
Data are presented as mean ± SEM.
(H) Glucose deprivation decreases lactate production in both DLD1-PROX1 and control cells. ECAR was measured in cells cultured at two different densities.
Data are presented as mean ± SEM.
(I) PROX1+, but not control, cells increase oxidative phosphorylation in the absence of glucose. OCR was measured in the same samples as for (H). Data are
presented asmean ±SEM. Two-way ANOVA; *p < 0.05; **p < 0.005; ***p < 0.001; red *, PROX1 versus control in indicated condition; black *, significant change of
the same cell type in different conditions.
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As PROX1 promoted survival of both DLD1 and SW480R cells,
we reasoned that important direct targets should be repressed in
both cell lines. To identify such targets, we combined ChIP-seq
data with gene expression profiling results in two cell types. We
identified 40 genes, repressed by PROX1 and carrying PROX1-
binding sites (FDR < 0.05; Tables S1, S2, and S3), out of which
seven genes (ABAT, BCL2L15, CAV1, IQGAP2, SEMA3C,
SLC7A7, and TNFRSF9) were repressed by PROX1 more than
2-fold (Figures 7A, S7C, and S7D). For most of these genes,
the direct connection to CRC progression remains to be investi-
gated. However, BCL2 family member, BCL2L15, acts as a con-
ditional pro-apoptotic gene in CRC cells in vitro (Dempsey et al.,
2005) and Cav1/ mice have more aggressive lesions in a ge-
netic model of intestinal cancer (Friedrich et al., 2013).
We tested next whether metabolic stress conditions affected
the expression of BCL2L15 and CAV1. Hypoxia induced expres-
sion of BCL2L15 and CAV1 in PROX1, but not PROX1+ cells,
suggesting that they act as PROX1 effectors in cells under meta-
bolic stress (Figures 7B and 7C). At the same time, PROX1+ and
PROX1 cell response to hypoxia was comparable, as judged by
expression levels of the HIF1a target VEGF-A (Figure 7D). We
overexpressed BCL2L15, CAV1, or another PROX1 target
TNFRSF9 in PROX1+ CRC cells (Figure S7E) and tested growth
and survival of these cells under normoxia and hypoxia.
BCL2L15 and, to a lesser extent, CAV1 reduced proliferation
and increased apoptosis of PROX1+ cells under hypoxia (Figures
7E, 7F, and S7F). In contrast, overexpression of TNFRSF9 had
no effect (Figure S7F). Furthermore, BCL2L15 overexpression
in PROX1+ CRC cells drastically reduced the number and size
of metastases after intravenous (i.v.) injections (Figures 7G–7J).
To test the effects of BCL2L15 inactivation, we used the AKP
intestinal organoid model, in which Bcl2l15 is expressed in
Prox1-negative cells and is further induced after Prox1 depletion
(Figures S7G and S7H). We found that Bcl2l15 depletion
enhanced clonogenic growth of intestinal organoids in vitro (Fig-
ures 7K and S7I), as well as proliferation and growth of organoid-
derived tumors in vivo (Figures 7L–7N and S7J), without affecting
cell survival (Figure 7O). As expected, Prox1 depletion reduced
colony formation and tumor growth under the same conditions
(Figures 7K–7O, S7I, and S7J).
To further analyze the significance of BCL2L15 and CAV1
regulation by PROX1 in human CRC in vivo, we studied
BCL2L15 and CAV1 protein localization in human CRC.
BCL2L15 and PROX1 displayed amutually exclusive localization
pattern both in metastases and primary tumors (Figures 7P and
S7K; data not shown). In contrast, CAV1 was generally low in
CRC cells independently of PROX1 status (data not shown).
These results suggest that BCL2L15 suppression is a more-spe-
cificmarker for PROX1 activity. Moreover, luciferase reporter as-
says showed that PROX1 directly repressed the activity of the 30
PROX1-binding region in the BCL2L15 locus (Figures S7L and
S7M). BCL2L15 mRNA levels were also strongly reduced in
CRC tumors (n = 230; p = 2.11 3 108; Figure 7Q) and showed
a significant negative correlation with PROX1 (Figure 7Q; p = 1.8
3 104). In summary, our genome-wide analyses identified a
number of potential direct PROX1 targets in CRC (Table S1),
whose roles still need to be investigated. Here, we show that
BCL2L15 is an important, even if likely not the only, effector ofCell RePROX1 in CRC, whose suppression in part recapitulates the
effects of PROX1.
DISCUSSION
We report that the colon-cancer-specific Wnt target PROX1 is
highly expressed in colon cancer metastases, where it is present
in a subset of cancer stem/progenitor cells. We also show that, in
advanced CRC, PROX1 sustains growth of macrometastases
through the evasion of apoptosis andmetabolic adaptation. Pre-
vious studies investigated the mechanisms of local invasion in
primary CRC tumors. They established important roles for Wnt
and Notch signaling, EMT, and the tumor-stroma interactions
(e.g., Dolznig et al., 2011; Sonoshita et al., 2011; Spaderna
et al., 2008; Wolf et al., 2012). However, mechanisms governing
outgrowth ofmetastases are not well understood. Yetmetastatic
CRC is a major clinical challenge, with limited patient survival
and few therapeutic options available, especially for patients
with activating KRAS mutations, which confer resistance to
anti-EGFR therapy (Cunningham et al., 2010; Van Emburgh
et al., 2014).
In this study, we investigated the role of the transcription factor
PROX1 in the development of CRC metastases. Expression of
PROX1 in primary CRC tumors is not an independent prognostic
factor (Skog et al., 2011). However, we found that PROX1 levels
are generally increased in metastases and a proportion of
PROX1 primary tumors give rise to PROX1+ metastases. Large
expression data sets from metastatic lesions will clarify whether
high levels of expression of PROX1 in a metastasis correlates
with survival after relapse. Nevertheless, already now our data
suggest that, in advanced CRC, PROX1 may be important in
the context of metastatic disease.
Analysis of PROX1 expression patterns in human metastases
and mouse models demonstrated that PROX1 is expressed only
upon transformation and it may delineate a distinct subpopula-
tion of cancer stem/progenitor cells. Furthermore, in vitro ana-
lyses of the intestinal organoid model demonstrated that, while
Prox1 does not directly control the expression of stem/progeni-
tor-associated genes or general Wnt pathway activity, it is
essential to maintain clonogenic growth. Our data are in agree-
ment with the results of Wiener et al., who show that Prox1 is
essential for the expansion of the stem cell pool in transformed
but not in normal intestinal stem cells (Wiener et al., 2014).
Through the analysis of mouse models of CRC metastasis, we
found that PROX1 is dispensable for growth of primary tumors,
cell survival in the bloodstream, or extravasation; however, it
promotes outgrowth of metastases. At least in part, this property
of PROX1 relies on its ability to override cell death imposed by
metabolic stress, such as hypoxia or low-nutrient environment.
Taken together, our data suggest that, in CRCmetastases, there
exists a subpopulation of PROX1+ stem/progenitor cells, which
are highly resistant to metabolic insults and can thus fuel meta-
static growth. These data identify PROX1 as an important player
in CRC stem/progenitor cells maintenance and function.
To investigate the mechanisms of PROX1 action in CRC, we
carried out PROX1 genome location analysis and identified
genes regulated by PROX1. As expected, a significant number
of direct PROX1 target genes were identified (Table S1), andports 8, 1957–1973, September 25, 2014 ª2014 The Authors 1967
(legend on next page)
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we began investigating their individual contribution. Here, we
show that a pro-apoptotic member of the BCL2 family,
BCL2L15 (Dempsey et al., 2005), is induced in hypoxic PROX1,
but not PROX1+, cancer cells and that BCL2L15 can in part reca-
pitulate the phenotype of PROX1 deficiency, such as increased
clonogenic growth of tumor organoids or tumor development
in vivo. These results indicate that apoptosis evasion under
metabolic stress conditions is important for the prosurvival func-
tion of PROX1+ in metastases. Most likely, the role of other
potentially interesting targets and their combinatorial interac-
tions will need to be addressed in the future. Of interest, Annexin
A1, identified as a PROX1 effector by Wiener et al. (2014) is
another direct target of PROX1 in our data set (Table S1).
With few exceptions, transcription factors are considered
undruggable. To overcome this limitation, we searched for
pharmacological approaches to target PROX1+ tumor cells.
We found that inhibition of autophagy, a catabolic process
providing an alternative energy source, eliminates the growth
advantage of PROX1+ CRC cells and decreases metastatic
burden. Of interest, following CQ treatment, viable tumor cells
are located in the vicinity of blood vessels and they remain
accessible for cytotoxic drugs. Thus, a combination of targeted
anti-PROX1 therapy with antiproliferative/cytotoxic 5-fluoro-
uracil-based chemotherapy might be pursued as a potential
treatment option for CRC patients with PROX1+ metastatic
disease.
We propose the following working model of PROX1’s role in
metastasis: high Wnt signaling induces PROX1 expression in
CRC cells and PROX1+ cancer stem/progenitor cells becomeFigure 6. Therapeutic Potential of Targeting PROX1
(A) PROX1 depletion in established metastases prevents further growth. SW480R
detected by in vivo bioluminescence imaging. Insert: macroscopic liver metastase
way ANOVA; ***p < 0.001. Data are presented as mean ± SEM.
(B) PROX1 suppression does not affect weight of primary tumors. Data are pres
(C) PROX1 suppression prevents further growth of metastases. ***p < 0.001. Da
(D) Inhibition of autophagy prevents PROX1-dependent adaptation to hypoxia.
normoxic or hypoxic conditions in the presence or absence of 5 mM CQ. Stainin
represents 50 mm.
(E) Quantification of cell proliferation. *p < 0.05; ***p < 0.001. Data are presented
(F) Low-dose CQ does not affect metastases size. Quantification of metastases
from day 7 post-implantation. Both necrotic and live tumor areas of metastases
appearance.
(G) CQ treatment induces necrosis in metastases. Quantification of necrotic are
evaluated at tumor-stromal interface, metastasis center, and in the entire lesion.
(H) Low-dose CQ does not affect blood-vessel density. Left column: staining for e
(blue). Yellow scattered line: highly vascularizedmetastatic area close to the liver s
Right column: staining for PROX1 (red), blood vessel marker endomucin (green),
(I) CQ treatment reduces proliferation of PROX1+ metastases but has little effect
White scattered lines, tumor area; white asterisk, areas of necrosis; yellow arrow
(J) Quantification of proliferation in orthotopic SW620 shCtr or shPROX1 primary
mean ± SEM.
(K) CQ treatment reduces proliferation of PROX1+ metastases. Staining for EdU
SW620 shCtr or shPROX1 primary tumors or metastases following treatment wit
(L) Quantification of proliferation as determined by EdU incorporation. Data are p
(M) CQ treatment induces necrosis in PROX1+ metastases. Data are presented a
(N) Higher autophagic flux in metastases as compared to primary tumors. Staini
pimonidazole (green). The scale bar represents 25 mm.
(O) Quantification of LC3B+ cancer cells in primary tumors and metastases. Data
(P) Quantification of LC3B+ foci in individual cells. Two-way ANOVA; *p < 0.05; *
(Q) Examples of images used for quantification in (O) and (P). Staining for LC3B
Cell Reresistant to metabolic stress, in part through the repression of
BCL2L15. Because PROX1 is produced only in CRC, but not
normal stem cells, and metabolic stress is high in metastases,
these data provide one of the mechanisms of how oncogenic
Wnt signaling induces cancer cell adaptation and promotesmet-
astatic cell outgrowth.
A related intriguing question is whether increased fitness of
PROX1+ tumor cells reflects the role of PROX1 in normal tissues.
The highest levels of Prox1 are found in lens fiber cells (Oliver
et al., 1993). The lens is an avascular organ, located in a physio-
logically hypoxic and glucose-poor environment (Mathias et al.,
1997; Trayhurn and Van Heyningen, 1972), and it is not fully un-
derstood how the lens maintains homeostasis in such condi-
tions. Similarly, PROX1+ lymphatic vessels, unlike blood vessels,
do not need basementmembrane or pericytes to survive, grow in
relatively hypoxic environment, and do not regress after removal
of proliferative stimuli (Baluk et al., 2005). Thus, it seems plau-
sible that PROX1 enhances adaptation of normal cells to unfa-
vorable metabolic conditions.
An important observation of this study is the differential role
of PROX1 in metastases versus primary tumors in advanced
colorectal cancer. In our models, all of which carry mutations
in oncogenic and tumor suppressor genes APC, KRAS, and
TP53, PROX1 suppression decreasedmetastasis size and prolif-
eration, whereas having little effect on the size or proliferation of
primary tumors. Whereas the mechanisms are yet unknown, we
propose that PROX1 is needed to provide a survival advantage
to metabolically stressed cells. This is supported by the fact
that CQ treatment is more effective in reducing growth of/PROX1si cells, implanted intracecally into NOD-SCID; IL-2Rg/ mice, were
s in control SW480R/PROX1si mouse. The scale bar represents 750 mm. Two-
ented as box and whiskers; Tukey appearance.
ta are presented as box and whiskers; Tukey appearance.
CQ, chloroquine. SW620 shCtr or shPROX1 cells were cultured for 72 hr in
g for phosphohistone H3 (red), GLUT1 (green), and DNA (blue). The scale bar
as mean ± SEM.
area in mice injected i.v. with tumor cells and treated with 10 mg/g CQ or PBS
>100 mm2 were quantified. Data are presented as box and whiskers; Tukey
as in liver metastases in mice treated with 10 mg/g CQ or PBS. Necrosis was
**p < 0.01; ***p < 0.001. Data are presented as mean ± SEM.
ndothelial marker endomucin (green), phosphohistone H3 (light blue), and DNA
troma.White scattered line: the necrotic area. The scale bar represents 200 mm.
and DNA (blue). The scale bar represents 100 mm.
on primary tumors. Staining for PH3 (light blue), PROX1 (red), and DNA (blue).
s, PH3+ cells. The scale bar represents 100 mm.
tumors or metastases. Two-way ANOVA; ***p < 0.001. Data are presented as
(red), PROX1 (light blue), pimonidazole (green), and DNA (blue) of orthotopic
h PBS or CQ. The scale bar represents 200 mm.
resented as mean ± SEM.
s mean ± SEM.
ng for LC3B (red) and DNA (blue). Hypoxic areas are identified by staining for
are presented as mean ± SEM.
*p < 0.01. Data are presented as mean ± SEM.
(red) and DNA (blue). The scale bar represents 2 mm.
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Figure 7. BCL2L15 Is a Direct PROX1 Effector Gene
(A) Heatmaps of selected PROX1 targets in two cells lines.
(B–D) BCL2L15 andCAV1 are induced in hypoxia in the absence of PROX1. Quantitative PCR analysis of the indicated transcripts. Cells were cultured in normoxia
or hypoxia for 24 hr. Data are presented as mean ± SEM.
(E and F) BCL2L15 and CAV1 suppress cell proliferation and induce apoptosis in hypoxia. Cells were cultured for 72 hr in normoxia or 0.1% O2. Proliferating or
apoptotic cells were identified by staining for phosphohistone H3 or activated caspase-3. Two-way ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001. Data are presented
as mean ± SEM.
(legend continued on next page)
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PROX1+ metastasis versus primary tumors and that metastases
have higher levels of autophagy. Interestingly, whereas generally
PROX1 increases metastases size, PROX1+ and PROX1 me-
tastases have a comparable size in skeletal muscle (Figure 3E).
These data indicate that metabolically active tissue such as skel-
etal muscle can complement the deficiency in PROX1. They also
highlight important differences in metabolism of metastases
versus primary tumors and further underscore a need to better
understand and exploit such differences.
Previous studies documented a critical role of stromal inflam-
mation, extracellular matrix, and chemokine/growth factor
signaling for the successful outgrowth of cancer cells (Chaffer
and Weinberg, 2011; Bhowmick, 2012; Zeelenberg et al.,
2003). Our work reveals a cancer-type-specific mechanism of
metastasis progression by demonstrating that the CRC-specific
Wnt target gene PROX1 increases metabolic fitness of metasta-
tic cancer stem cells. Importantly, all human and mouse models
used in the study carry an activatingmutation inKRAS, which un-
derlies intrinsic or acquired resistance to targeted anti-EGFR
therapies (Van Emburgh et al., 2014). PROX1 deficiency can
therefore override advantages gained through the activation
of KRAS signaling in Wnthigh cancer cells. Thus, targeting of
PROX1 and PROX1-dependent pathways should be further
explored for development of potential treatment approaches of
PROX1+ KRAS mutant, anti-EGFR-resistant CRC metastases.
EXPERIMENTAL PROCEDURES
Human Tumor Analyses
Use of human CRC samples was approved by the Canton of Vaud’s ethics
committee. See Supplemental Experimental Procedures for staining and
tumor sample information.
Bioinformatics Analyses
The correlation analysis of PROX1 expression with cell differentiation, prolifer-
ation, and stem cell markers was based on GSE41258 data set (Sheffer et al.,
2009). We used GSE33112 data set (de Sousa E Melo et al., 2011) to analyze
PROX1 levels in Wnthigh and Wntlow CSCs. See Supplemental Experimental
Procedures for the detailed description. PROX1 and BCL2L15 expression
was analyzed in 230 microsatellite stable colon tumors and 17 normal colon
tissues from The Cancer Genome Atlas (TCGA) data set COAD UNC_Illumina-
GA_RNASeqV2 (TCGA project: http://cancergenome.nih.gov/).(G) BCL2L15 limits growth of metastases. GFP- or BCL2L15-expressing SW620 c
PROX1 (green), EdU (red), and DNA (blue). The scale bar represents 100 mm.
(H) Quantification of metastasis size for data shown in (F). Data are presented as
(I) Metastasis incidence. Data are presented as mean ± SEM.
(J) BCL2L15 promotes tumor necrosis and reduces proliferation in metastatic PRO
± SEM.
(K) Depletion of Bcl2l15 increases clonogenicity of intestinal Apcfl/fl;KrasG12D;T
following seeding of 3,000 single cells per well, transduced with a nontargeting sh
box and whiskers; Tukey appearance.
(L) Bcl2l15 depletion promotes tumor growth. shBcl2l15, control nontargeting shR
into NOD-SCIDg/ mice. Two-way ANOVA; **p < 0.01; ***p < 0.001. Data are p
(M) Target protein expression, proliferation, and apoptosis in organoid-derived tu
DNA (blue). The scale bar represents 25 mm.
(N) Quantification of cell proliferation in organoid tumors. Data are presented as
(O) Quantification of apoptosis in organoid tumors. One-way ANOVA; *p < 0.05;
(P) Mutually exclusive localization of PROX1 and BCL2L15 in human CRCmetasta
represents 25 mm.
(Q) BCL2L15 mRNA is reduced in colon tumors and anticorrelates with PROX1 mR
normal colon samples.
Cell ReCell Lines and Culture Conditions
SW620, SW480, and DLD1 (CCL-227, CCL-228, and CCL-221; ATCC) cells
were used for generation of cell lines and spheroids as described in Sup-
plemental Experimental Procedures. ECAR and OCR were measured in
cells cultured for 24 hr prior to analysis according to the manufacturer’s
protocols (SeahorseBio), and all data were normalized to the total protein
content.
Animal Studies
Experiments were approved by the Animal Ethics Committee of the Canton of
Vaud or by the UK Home Office regulations. The complete list of mouse lines,
genotyping, and other procedures are provided in Supplemental Experimental
Procedures.
Staining Procedures
Staining procedures and list of antibodies are provided in Supplemental
Experimental Procedures. Metastases were quantified using staining for hu-
man vimentin or KRT20. We detected cell proliferation for phosphohistone
H3 (Cell Signaling Technology) and apoptosis by staining for cleaved
caspase-3 (CST) or by TUNEL assay (R&D Systems). We used Axiovision Im-
ager.Z1 or Zeiss LSM 510 META scanning confocal microscope for image
acquisition and Bitplane IMARIS Suite 6.3.1 and Adobe Photoshop CS6 for im-
age analyses.
RNA Isolation, Quantitative PCR, Microarray Analyses, and
Western Blotting
We used RNeasy columns (QIAGEN) for RNA isolation and Agilent 2100 Bio-
analyzer (Agilent) for RNA quality control. For transcriptome analyses, we
used RNA from DLD1, DLD1-PROX1, or SW480R cells, transfected with
10 nM PROX1 siRNAs and AllStars control siRNAs (QIAGEN). Affymetrix Hu-
man Gene 1.0 ST arrays (Affymetrix) were used for gene-expression profiling.
See Supplemental Experimental Procedures for list of siRNAs and primers.
We performed RT-PCR analyses on StepOnePlus or 7500-Fast real-time PCR
Systems (Applied Biosystems) with SYBR Green PCR Master Mix (Applied
Biosystems).
For western blotting, proteins were resolved by SDS-PAGE, transferred onto
Immobilon-P, and detected with horseradish-peroxidase-conjugated second-
ary antibodies (Dako) and enhanced chemiluminescence (Thermo Fisher
Scientific).
PROX1 ChIP-Seq and Reporter Analyses
Pools of three independent ChIP experiments and input DNA were used for
sequencing (see Supplemental Experimental Procedures).
ChIP-seq data, generation of BCL2L15 luciferase reporter constructs, and
their analyses are described in Supplemental Experimental Procedures.ells were injected i.v., and metastases were analyzed 30 days later. Staining for
mean ± SEM.
X1+ cells. Two-way ANOVA; *p < 0.05; **p < 0.01. Data are presented as mean
p53fl/fl;villin-CreERT2 (AKP) organoids. Colonies were quantified at day 15,
RNA (shCtrl) or shProx1. One-way ANOVA; ***p < 0.001. Data are presented as
NA (shCtrl), or shProx1-transduced organoid were implanted subcutaneously
resented as mean ± SEM.
mors. Staining for Prox1 (green), Bcl2l15, EdU or cleaved caspase-3 (red), and
mean ± SEM.
***p < 0.001. Data are presented as mean ± SEM.
ses. Staining for PROX1 (green), BCL2L15 (red), and DNA (blue). The scale bar
NA levels. Heatmap of PROX1 and BCL2L15 mRNA levels in CRC tumors and
ports 8, 1957–1973, September 25, 2014 ª2014 The Authors 1971
Statistical Analyses
Weused Prism5.0 for laboratory data analysis. p value% 0.05was considered
to be statistically significant. Full description of statistical analyses is provided
in Supplemental Experimental Procedures.
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